HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Cipla launches orally inhaled insulin in India
Dec-23-2025

Cipla has launched Afrezza (insulin human) Inhalation Powder in India. Afrezza is rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy. The launch of this product in India is expected to benefit many of the 10 crore adults currently living with diabetes mellitus. The company had obtained regulatory approval for the exclusive distribution and marketing of Afrezza from Central Drugs Standard Control Organisation (CDSCO) late last year.

Afrezza, which is created and manufactured by MannKind Corporation (MannKind) USA, dissolves rapidly upon oral inhalation and begins lowering blood glucose within around 12 minutes, closely mirroring the body’s natural insulin response. By offering a needle-free, rapid-acting alternative to daily prandial injections, it is designed to support better adherence and enable quicker glycemic control for adults with both type 1 and type 2 diabetes mellitus. This differentiated delivery system also helps address the emotional and practical barriers that often lead patients to delay or discontinue insulin therapy, which is a need that leading healthcare experts continue to highlight as critical in strengthening diabetes care.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

  RELATED NEWS >>